ArticleCNS neuroscience & therapeutics2026
Antithrombotic Therapy After Intracerebral Hemorrhage: Real-World Evidence for In-Hospital Resumption.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
background and purposePatients with intracerebral hemorrhage (ICH) who require antithrombotic therapy (AT) face competing risks of recurrent bleeding and ischemic events. Optimal timing of AT resumption during hospitalization remains uncertain. We evaluated whether restarting AT in hospitalized patients with acute spontaneous ICH reduces ischemic complications without increasing hemorrhagic risk.
methodsWe conducted a retrospective cohort study at Peking Union Medical College Hospital (2014-2022) including adults (≥ 18 years) admitted with spontaneous ICH within 6 months of onset. Patients were categorized as: Group 1, no AT indication; Group 2, AT indicated but not treated; Group 3, AT indicated and treated. Primary endpoints were ischemic events (ischemic stroke, transient ischemic attack, myocardial infarction, pulmonary embolism, deep venous thrombosis) and hemorrhagic events (new ICH or hematoma expansion ≥ 12.5 mL or ≥ 33%). Outcomes were assessed from onset to discharge.
resultsAmong 601 patients (median age 58 years; 40.3% female), 256 (42.6%) were in Group 1, 247 (41.1%) in Group 2, and 98 (16.3%) in Group 3. Median time from onset to AT resumption was 11 days (IQR 2-27). Restarting AT (Group 3) significantly reduced ischemic events (14.3% vs. 28.7%; adjusted HR 0.34, 95% CI 0.18-0.65) without increasing hemorrhagic events (5.1% vs. 6.3%; adjusted HR 0.67, 95% CI 0.20-2.19). Competing-risk models and sensitivity analysis confirmed these findings.
conclusionsIn-hospital resumption of AT after acute spontaneous ICH significantly decreased ischemic events without excess hemorrhagic risk, supporting its potential benefit in carefully selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.